Compared to Estimates, Pfizer (PFE) Q1 Earnings: A Look at Key Metrics

For the quarter ended March 2025, Pfizer (PFE) reported revenue of $13.72 billion, down 7.8% over the same period last year. EPS came in at $0.92, compared to $0.82 in the year-ago quarter.The reported revenue represents a surprise of -0.88% over the Zacks Consensus Estimate of $13.84 billion. With the consensus EPS estimate being $0.64, the EPS surprise was +43.75%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Oncology- Ibrance- United States: $659 million versus the three-analyst average estimate of $565.50 million. The reported number represents a year-over-year change of -3%. Revenues- Primary Care- Eliquis alliance revenues and direct sales- United States: $1.30 billion versus $1.39 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -8.1% change. Revenues- Specialty Care- Enbrel- Total International: $140 million versus the three-analyst average estimate of $132.28 million. The reported number represents a year-over-year change of -12%. Revenues- Oncology- Ibrance- Total International: $318 million versus $333.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -15.2% change. Revenues- Oncology- Ibrance- Worldwide: $977 million versus $898.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.3% change. Revenue- Specialty Care- Cibinqo: $58 million versus $71.20 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +38.1% change. Revenues- Specialty Care- Xeljanz- Worldwide: $128 million compared to the $141.92 million average estimate based on three analysts. The reported number represents a change of -34% year over year. Revenues- Oncology- Inlyta- Worldwide: $219 million compared to the $207.30 million average estimate based on three analysts. The reported number represents a change of -7.6% year over year. Revenue- Specialty Care- Worldwide: $3.99 billion versus the three-analyst average estimate of $3.98 billion. The reported number represents a year-over-year change of +3.8%. Revenue- Primary Care- Worldwide: $5.70 billion versus $5.82 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -21% change. Revenues- Oncology- Xtandi alliance revenues- United States: $458 million versus $419.37 million estimated by three analysts on average. Revenues- Oncology- Xtandi alliance revenues- Worldwide: $458 million compared to the $419.37 million average estimate based on three analysts. View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned -9% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks